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Abstract 
Aims: Ischaemic cardiovascular disease is a major cause of morbidity and mortality 
worldwide. Despite promising results from pre-clinical animal models, VEGF-based strategies 
for therapeutic angiogenesis have yet to achieve successful reperfusion of ischaemic tissues 
in patients. Failure to restore efficient VEGF activity in the ischaemic organ remains a major 
problem in current pro-angiogenic therapeutic approaches. Plasma membrane calcium 
ATPase 4 (PMCA4) negatively regulates VEGF-activated angiogenesis via inhibition of the 
calcineurin/NFAT signalling pathway. PMCA4 activity is inhibited by the small molecule 
aurintricarboxylic acid (ATA). We hypothesise that inhibition of PMCA4 with ATA might 
enhance VEGF-induced angiogenesis. 
Methods and Results: We show that inhibition of PMCA4 with ATA in endothelial cells 
triggers a marked increase in VEGF-activated calcineurin/NFAT signalling that translates into 
a strong increase in endothelial cell motility and blood vessel formation. ATA enhances VEGF-
induced calcineurin signalling by disrupting the interaction between PMCA4 and calcineurin at 
the endothelial-cell membrane. ATA concentrations at the nanomolar range, that efficiently 
inhibit PMCA4, had no deleterious effect on endothelial-cell viability or zebrafish embryonic 
development. However, high ATA concentrations at the micromolar level impaired endothelial 
cell viability and tubular morphogenesis, and were associated with toxicity in zebrafish 
embryos. In mice undergoing experimentally-induced hindlimb ischaemia, ATA treatment 
significantly increased the reperfusion of post-ischaemic limbs. 
Conclusions: Our study provides evidence for the therapeutic potential of targeting PMCA4 to 
improve VEGF-based pro-angiogenic interventions. This goal will require the development of 
refined, highly selective versions of ATA, or the identification of novel PMCA4 inhibitors.  
Keywords: PMCA4, angiogenesis, ATA, calcineurin/NFAT, VEGF  
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1. Introduction 
Ischaemic cardiovascular diseases (including ischaemic heart disease, peripheral arterial 
disease, and stroke) constitute a leading cause of morbidity and mortality worldwide [1]. In 
some patients, bypass surgery and interventional endovascular procedures can successfully 
restore blood flow to the ischaemic tissue [2,3]. However, the distribution and diffuseness of 
arterial occlusions preclude surgical revascularization in a high proportion of patients [3]. 
Therapeutic strategies to promote the formation of new blood vessels in the ischaemic organ 
(referred to as therapeutic angiogenesis) constitute a promising alternative for these patients 
[3-5].  
Angiogenesis, the formation of new blood vessels from pre-existing ones, is a tightly regulated 
process involving the participation of several pro- and anti-angiogenic factors [6]. One of the 
critical pro-angiogenic factors is vascular endothelial growth factor (VEGF) [7]. A number of 
gene-based and protein-based approaches have been developed to deliver exogenous VEGF 
to ischaemic tissues [5]. Data obtained in animal models of myocardial and limb ischaemic 
disease demonstrated that VEGF-based pro-angiogenic therapies induce successful 
reperfusion of the ischaemic organ [8]. Unfortunately, to date clinical translation of these 
procedures has produced only limited patient benefit [9]. The reasons for the lack of clinical 
success with therapeutic angiogenesis approaches are complex, but one central problem in 
current approaches is failure to restore efficient VEGF activity in the ischaemic organ [5,8,9]. 
Design of new, more effective treatments requires a deep understanding of the molecular and 
biochemical processes governing VEGF-induced angiogenesis.  
We recently reported a novel role for plasma membrane calcium ATPase 4 (PMCA4) as a 
negative regulator of VEGF-activated angiogenesis [10]. PMCAs are enzymatic high-affinity 
systems that export calcium from the cytosol to the extracellular environment [11]. There are 
four PMCA isoforms (PMCA1-4) encoded by four distinct genes [11]. PMCA1 and 4 are 
expressed ubiquitously, whereas PMCA2 and 3 are restricted to highly specialised cells and 
tissues [11]. PMCA4 is the major isoform present in endothelial cells [12]. Our previous work 
showed that PMCA4 attenuates VEGF-induced angiogenesis by establishing an inhibitory 
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interaction with the signalling protein calcineurin [10]. Calcineurin is a serine/threonine 
phosphatase activated by increases in cytosolic calcium concentration [13]. Activated 
calcineurin mediates dephosphorylation of NFAT (nuclear factor of activated T cells) 
transcription factors, promoting their translocation to the nucleus and the subsequent 
expression of NFAT-target genes [14]. The calcineurin/NFAT signalling axis plays a critical 
role in VEGF-induced angiogenesis [15,16]. PMCA4 is thought to downregulate calcineurin 
activity by tethering it to low-calcium micro-domains created by the pump’s calcium expulsion 
action and, in so doing, impair VEGF-activated pro-angiogenic signalling [10]. We therefore 
hypothesize that pharmacological blockade of PMCA4 function, and thus suppression of the 
negative effect of PMCA4 on angiogenesis, might potentiate the efficiency of therapeutic 
strategies involving VEGF. Supporting this possibility, we previously reported more efficient 
limb reperfusion in PMCA4-/- knockout mice undergoing femoral artery ligation than in their 
wild-type littermates [10].  
A recent study showed that low concentrations of the small molecule aurintricarboxylic acid 
(ATA) strongly inhibit the calcium extrusion activity of PMCA4 without affecting the activity of 
PMCA1 or other major calcium pumps such as SERCA and the Na+/K+ ATPase [17]. This 
finding prompted us to examine whether inhibition of PMCA4 with ATA enhances VEGF-
induced angiogenesis. 
Here, we show that treatment of primary endothelial cells with low concentrations of ATA 
results in a remarkable increase in VEGF-mediated activation of the calcineurin/NFAT 
pathway and in the expression of the VEGF-induced, NFAT-dependent, pro-angiogenic protein 
RCAN1.4. Inhibition of PMCA4 with ATA also enhances endothelial cell motility and tubular 
morphogenesis, with no harmful effects on the cells. These results highlight the clinical 
potential of targeting PMCA4 to improve VEGF-based therapeutic interventions that promote 
blood vessel formation in patients suffering from ischaemic cardiovascular disease.   
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2. Materials and methods 
2.1. Cells and Cell Culture  
Human umbilical vein endothelial cells (HUVEC) were purchased from TCS Cellworks and 
cultured in tissue culture flasks pre-coated with 0.1% gelatin in endothelial cell growth medium 
(ECGM, PromoCell) supplemented with ECGM-supplement mix and 1% 
penicillin/streptomycin/amphotericin B (Sigma-Aldrich). HUVECs were used at passages 6-8. 
Mouse lung endothelial cells (MLEC) were purified from wild-type or PMCA4-null mice as 
described [10]. Generation and characterization of PMCA4 knockout mice has been previously 
reported [18]. 
2.2. Luciferase reporter assay 
HUVECs were infected with Ad-NFAT-Luc (a replication-deficient adenovirus harbouring an 
NFAT-dependent, luciferase-based reporter system) at a multiplicity of infection (MOI) of 50. 
Generation of Ad-NFAT-Luc-infected particles was as described [10]. Infected cells were 
incubated in ECGM containing 0.5% fetal calf serum for 16 hours and then stimulated with 
VEGF (25 ng/ml) for 6 hours. Luciferase activity was determined as described [19].  
2.3. siRNA gene knock-down 
siRNA-mediated knock-down of PMCA4 gene expression was performed using “ON-TARGET-
plus SMART pool human ATP2B4” (Thermo Scientific). “ON-TARGET-plus non-targeting pool 
control duplexes” (Thermo Scientific) was used as a control.   
For siRNA transfection, HUVECs were plated in 0.1% gelatin pre-coated 6-well tissue culture 
plates (3 x 105 cells/well) and incubated overnight. The following morning, cells were washed 
with PBS and incubated in serum-free, antibiotic-free OPTIMEM medium for 1 hour. Then, 100 
pmol of siRNA/well were transfected using 5 μl of Lipofectamine 2000 (Thermo Scientific). 
Transfection medium was removed after incubation for 6 hours, and substituted by ECGM 
supplemented with ECGM-supplement mix and 1% penicillin/streptomycin/amphotericin B 
(Sigma-Aldrich). Cells were incubated for 72 hours and then used for further experiments.  
Quantitative Real-Time PCR 
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Total RNA from HUVECs was extracted using the “Total RNA purification kit” (Norgen) and 
cDNA synthesis was performed with 0.5 μg of total RNA using the “High capacity cDNA 
reverse transcription kit” (Applied Biosystems). PMCA4 RNA expression was determined by 
qRT-PCR using TaqMan Gene Expression Assay (Hs00608066_m1) in a 7500 Fast Real-
Time PCR System (Applied Biosystems, UK). PCR cycling conditions consisted of an initial 
enzyme activation step at 95°C for 10 minutes, followed by denaturation at 95°C for 15 
seconds, and annealing and extension at 60°C for 1 minute for 40 cycles. Ct value was 
normalized using the Ct values for the housekeeping gene Hprt-1 (TaqMan Gene Expression 
Assay, Hs99999909_m1). Analysis of data was carried out using the comparative 2-ΔΔCT 
method. 
2.4. Western Blot 
Total proteins were isolated by direct lysis of HUVECs, treated as indicated, in NuPAGE LDS 
sample buffer containing 0.05% β-mercaptoethanol. Membrane-associated proteins were 
isolated using the ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem) as reported 
[20]. 
We have noticed that repeated and prolonged boiling degrades endothelial PMCA4; therefore 
we minimised repeated cycles of freeze-thawing-boiling. Protein samples were boiled for 1 
minute and then resolved by SDS-PAGE as described [21]. Antibody sources and conditions 
are described in detail in the online Supplementary Material. 
2.5. Immunoprecipitation 
HUVECs were stimulated for 4 hours with VEGF (25 ng/ml) in the presence of ATA (250 nM) 
or vehicle (DMSO), and PMCA4/calcineurin complexes were immunoprecipitated from 4 mg 
total protein extract with anti-calcineurin A monoclonal antibody (Sigma) using the Pierce Co-
Immunoprecipitation Kit. To immunoprecipitate the PMCA4/eNOS complex, the same 
conditions were used except that cells were treated for only 5 minutes and protein lysates 
were incubated with anti-PMCA 5F10 monoclonal antibody. 
Levels of PMCA4, calcineurin, or eNOS in the immunoprecipitates were determined by 
western blot using anti-PMCA4 (JA3), anti-calcineurin A, or anti-eNOS antibodies. 
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2.6. Wound healing migration assay 
Cell migration of HUVECs and MLECs, treated as indicated, was assayed using the 
CytoselectTM 24-well Wound Healing Assay kit (Cell Biolabs). Images were captured with a 
Nikon DSFi1 digital camera coupled to a Nikon ECLIPSE TS100 microscope at 4x 
magnification. Cell-free area was quantified with ImageJ software. 
2.7. Matrigel tube-formation assay 
HUVECs were plated onto Geltrex Reduced Growth-Factor Matrix (Invitrogen) in Medium 200 
with no phenol red and supplemented with 2% fetal calf serum and 50 ng/ml growth factor 
(VEGF or bFGF) in the presence of ATA at the indicated concentration or DMSO as a control. 
Tube formation was quantified after incubation at 37°C for 16 hours. Images were recorded 
with a Nikon DSFi1 digital camera coupled to a Nikon ECLIPSE TS100 microscope at 4x 
magnification. 
2.8. MTT assay 
HUVECs were seeded on 96-well tissue culture plates (without gelatin pre-coating) at a 
density of 2.5 x 104 cells/well in supplemented ECGM (PromoCell). Cell viability was 
determined by MTT assay [22] the morning after cell plating (Time=0) and then after 3 and 6 
days of incubation in supplemented ECGM containing VEGF (25 ng/ml) and ATA at the 
indicated concentration or DMSO as control.   
2.9. Zebrafish embryo viability 
Zebrafish embryos Tg(kdrl:HRAS-mCherry; flk1:EGFP-nls) [23,24] were manually 
dechorionated and incubated in increasing concentrations of ATA or DMSO from 30 hours 
post fertilisation (hpf) for 24 hours. Vascular morphology was imaged at 54 hpf using a Zeiss 
Lightsheet Z.1 microscope. Experiments were performed under UK Home Office licence 
40/3708. 
2.10. Murine hindlimb ischaemia 
Unilateral hindlimb ischaemia was induced by femoral artery ligation in 12-week-old C57/BL6 
mice anaesthetised with 2% isoflurane via inhalation. To induce hindlimb ischaemia 
maintaining minimal blood flow to the limb, we ligated a short fragment of the femoral artery in 
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proximal and distal positions and excised the intervening segment (this procedure corresponds 
to the experiments shown in Fig 7). In a separate set of experiments, to totally blunt blood flow 
to the limb, we performed femoral ligation and excision of the intervening segment but on this 
occasion we ligated and excised a longer femoral segment to induce deep acute ischaemia 
(this procedure corresponds to the experiments shown in Fig S5). In all cases, ATA (5 mg/kg) 
or DMSO (vehicle) was administered intraperitoneally 2 hours after the operation, and then 
daily as indicated. Blood flow was measured in the sham-operated and ischaemic limbs of 
anaesthetised animals before surgery, 2 hours after the operation, and at the indicated times 
using a Laser Doppler Perfusion Imager System (Moor Instruments). Mice were sacrificed in 
an euthanasia chamber with 70% CO2. 
Mouse studies were approved by Animal Care and Ethics committee at the Centro Nacional 
de Investigaciones Cardiovasculares and conformed to directive 2010/63EU and 
recommendation 2007/562/EC regarding the protection of animals used for experimental and 
other scientific purposes. 
2.11. Nitric oxide determination 
To determine intracellular nitric oxide bioavailability HUVECs were incubated for 3 hours in 
basal ECGM (Promocell) containing 0.5% fetal bovine serum (FBS). After serum starvation, L-
arginine was added to a 100 µM final concentration and cells were incubated for 15 minutes. 
Cells were then loaded for 30 minutes with 10 µM of the NO-sensitive fluorescence probe 
DAF-FM (Molecular Probes). Dye-containing medium was removed and replaced with basal 
ECGM, 0.5% FBS. Cells were incubated for 45 minutes at 37°C, and then NO synthesis was 
induced by stimulation for 5 minutes with VEGF (25 ng/ml) in the presence of ATA (250 nM) or 
vehicle (DMSO). After treatment, cells were washed with PBS and fixed in formalin (Sigma). 
DAF-FM fluorescence was detected using a ZEISS LSM 880 confocal laser scanning 
microscope.    
2.12. Immunohistochemistry 
Tibialis muscle isolated from non-ischaemic (sham-operated) or ischaemic limbs were fixed in 
4% formalin solution, then incubated in 30% saccharose solution, embedded in OCT, frozen in 
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liquid nitrogen, and finally cut on a cryotome. VEGF expression was detected by 
immunohistochemistry using a 1:750 dilution of an anti-VEGF-A rabbit polyclonal antibody (1 
mg/ml, Sigma-Aldrich). A biotinylated anti-rabbit IgG was used as secondary antibody at a 
1:500 dilution. Samples were incubated with a 1:500 dilution of HPR-conjugated streptavidin. 
Substrate staining was developed with diaminobenzidine (DAB; Vector Laboratories). 
2.13. Statistical analysis 
Results are shown as mean ± S. E. Significance of differences between two groups was 
analysed by unpaired, two-tailed Student’s t test. One-way ANOVA with post hoc Tukey’s 
comparison test was used for comparison among groups. Differences were considered 
statistically significant at P ≤ 0.05.  
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3. Results 
3.1. ATA enhances VEGF-induced calcineurin signalling in endothelial cells by disrupting the 
PMCA4/calcineurin interaction 
Our previous work demonstrated that PMCA4 negatively modulates VEGF-induced activation 
of the calcineurin/NFAT signal transduction pathway in endothelial cells [10]. The identification 
of the small molecule ATA as a PMCA4 inhibitor [17] prompted us to investigate whether ATA-
mediated PMCA4 inhibition potentiates VEGF-induced calcineurin/NFAT signalling.  
To explore this possibility, primary HUVECs were infected with the NFAT-dependent, 
luciferase-based adenoviral reporter vector Ad-NFAT-Luc. Inhibition of PMCA4 is reached at 
low ATA concentrations in the range of 250 nM [17]. We therefore used this concentration of 
ATA in our experiments to achieve inhibition of PMCA4 while avoiding inhibitory effects on 
other cellular proteins that have been shown to require much higher ATA concentrations to be 
inhibited. Treatment of Ad-NFAT-Luc-infected HUVECs with 250 nM ATA increased VEGF-
induced calcineurin/NFAT pathway activation by 78.1% (Fig 1A).  
Further analysis on the functional consequences of boosting calcineurin signalling with ATA 
showed that VEGF-induced protein expression of the NFAT-dependent gene RCAN1.4 was 
also significantly enhanced (56.8%) by ATA treatment (Fig 1B). 
These data indicate that ATA potentiates the VEGF-induced activation of the calcineurin/NFAT 
pathway in endothelial cells, and that this effect is translated into enhanced expression of 
NFAT-target genes such as RCAN1.4.   
PMCA4 is thought to downregulate calcineurin/NFAT pathway activity through a molecular 
interaction that sequesters calcineurin into low-calcium micro-domains created by the pump’s 
calcium extrusion activity [25]. Supporting this idea, disruption of the PMCA4/calcineurin 
interaction notably potentiates calcineurin/NFAT signalling [10]. We therefore next examined 
whether the ATA-enhanced calcineurin signalling is associated with changes in the interaction 
between the two proteins. Membrane-associated proteins were isolated from HUVECs treated 
with VEGF in the presence or absence of ATA and analysed for the content of PMCA4 and 
calcineurin. ATA treatment significantly reduced the level of membrane-associated calcineurin, 
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whereas the levels of PMCA4 remain unaffected (Fig 2A), suggesting that treatment of 
HUVECs with ATA releases calcineurin from its interaction with PMCA4 in the plasma 
membrane. Analysis of whole-cell extracts revealed similar levels of calcineurin in control 
(DMSO) and ATA-treated cells, excluding an effect of ATA on calcineurin expression (Fig 2B). 
Total levels of PMCA4 were similarly unaffected in the same samples (Fig 2B).  
To confirm that the decrease in membrane-associated calcineurin was due to disruption of the 
PMCA4/calcineurin interaction, we performed immunoprecipitation experiments. Protein 
extracts from HUVECs stimulated with VEGF in the presence or absence of 250 nM ATA were 
immunoprecipitated with anti-calcineurin antibody. Western blot analysis of the 
immunoprecipitated proteins revealed that ATA treatment markedly reduced the amount of 
PMCA4 co-precipitated with calcineurin, suggesting dissociation of the PMCA4/calcineurin 
complex (Fig 2C). No significant differences were found in the amount of immunoprecipitated 
calcineurin in control and ATA-treated cells (Fig 2C), excluding an effect of ATA on the affinity 
of the immunoprecipitating antibody for calcineurin. 
Together, these data suggest that treatment of endothelial cells with ATA liberates calcineurin 
from its interaction with PMCA4, thereby potentiating VEGF-mediated activation of 
calcineurin/NFAT signalling and the subsequent expression of NFAT-target genes such as 
RCAN1.4. 
3.2. ATA increases VEGF-mediated endothelial cell motility and blood vessel formation 
PMCA4-mediated inhibition of calcineurin/NFAT signalling negatively regulates endothelial cell 
migration and tubular morphogenesis [10]. The enhanced calcineurin/NFAT signalling induced 
by ATA in VEGF-stimulated HUVECs (Fig 1) suggested that ATA might reverse the negative 
effect of PMCA4 on these angiogenic processes.  
In wound-healing migration assays, exposure of VEGF-stimulated HUVECs to ATA increased 
cell migration by 58.4% (Fig 3A).  
To determine whether the ATA-dependent increase in endothelial cell motility involves PMCA4 
inhibition, and is not the consequence of off-target effects, migration assays were conducted 
with mouse lung endothelial cells (MLECs) isolated from PMCA4-/- knockout mice or their 
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wildtype littermates. Consistent with our published observations [10], PMCA4-deficient cells 
migrated over longer distances than their wildtype counterparts (Fig 3B). However, whereas 
ATA increased wildtype MLEC migration by 64.7%, it had no effect on the migration of 
PMCA4-deficient MLECs (Fig 3B).  
To investigate whether the ATA-mediated enhanced endothelial cell motility is linked to 
disruption of the PMCA4/calcineurin interaction, we performed cell migration assays using 
HUVECs infected with Ad-ID4, an adenoviral vector encoding a PMCA4 region that 
successfully disrupts association between the two proteins [10]. As a control, HUVECs were 
infected with an adenovirus encoding β-Galactosidase (Ad-LacZ). ATA increased the migration 
of Ad-LacZ-infected cells (Fig 3C). As we previously reported [10], disruption of the 
PMCA4/calcineurin interaction in Ad-ID4-infected HUVECs increased cell migration (Fig 3C), 
however ATA-treatment did not further increase migration (Fig 3C). Ad-ID4-infected cells 
treated with DMSO or ATA expressed equal amounts of ID4, excluding an effect of ATA on 
adenovirus infection efficiency (Fig S1). These data not only confirm the implication of PMCA4 
in ATA-enhanced endothelial cell migration, but also reveal that disruption of the interaction 
between PMCA4 and calcineurin is a key molecular mediator of this process. 
PMCA4 and the calcineurin/NFAT pathway both have well-established roles in the regulation 
of blood vessel formation [10,15,16]. We therefore next investigated the effect of ATA on 
endothelial cell tubular morphogenesis. Consistent with previous studies [10,16], VEGF 
increased the ability of HUVECs to form capillary-like structures in Matrigel assays (Fig 4A). 
VEGF-induced tube formation was further enhanced by co-treatment with ATA (38.9% 
increase with respect to control cells) (Fig 4A). To substantiate the involvement of PMCA4 on 
the boost in VEGF-induced endothelial cell tubular morphogenesis exerted by ATA, we 
suppressed PMCA4 expression in endothelial cells using siRNA-mediated technology (Fig 
S2). ATA significantly enhanced endothelial cell tubular morphogenesis in VEGF-stimulated 
cells transfected with a control non-target siRNA (si-NT) (Fig 4B). As expected, suppression of 
PMCA4 expression in cells transfected with siRNA targeting PMCA4 (si-PMCA4) increased 
the ability of the cells to form capillary-like structures in response to VEGF (Fig 4B), however 
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ATA failed to further increase tubular morphogenesis in these cells (Fig 4B). This result 
demonstrates the involvement of PMCA4 in the enhancement of blood vessel formation 
induced by ATA in endothelial cells stimulated with VEGF. 
Interestingly, ATA did not boost tubular morphogenesis in HUVECs stimulated with basic 
fibroblast growth factor (bFGF), a pro-angiogenic factor that does not activate calcineurin 
signalling [16] (Fig 4C).  
These observations suggest that inhibition of PMCA4 with ATA markedly enhances VEGF-
induced endothelial cell motility and tubular morphogenesis in a calcineurin/NFAT-dependent 
manner.  
Altogether, these results highlight the clinical potential of PMCA4 inhibition and/or disruption of 
the PMCA4/calcineurin interaction to design novel therapeutic approaches that improve 
VEGF-induced angiogenesis in patients with cardiovascular ischaemic disease. 
3.3. ATA promotes PMCA4/eNOS interaction and attenuates nitric oxide synthesis in 
endothelial cells 
Our results in this work establish a major role for the calcineurin/NFAT signalling pathway in 
the enhancement of VEGF-induced angiogenesis upon inhibition of PMCA4 with ATA; 
however, they do not exclude the potential participation of other signalling pathways. In 
addition to calcineurin, we recently showed that PMCA4 also downregulates the activity of 
eNOS and the subsequent production of nitric oxide (NO) in endothelial cells [26]. The pro-
angiogenic properties of NO are well established [27, 28], and VEGF activates eNOS-
mediated NO production in endothelial cells [29]. Thus we decided to investigate the effect of 
ATA on the PMCA4/eNOS interaction, and in the induction of NO synthesis mediated by 
VEGF in endothelial cells. For this purpose, protein lysates isolated from HUVECs stimulated 
with VEGF in the presence or absence of 250 nM ATA were immunoprecipitated with the anti-
PMCA antibody 5F10. Western blot analysis of immunoprecipitated proteins showed that ATA 
strongly increased the amount of eNOS co-precipitated with PMCA4 (Fig 5A). No significant 
differences were observed in the amount of PMCA4 precipitated in control or ATA-treated cells 
(Fig 5A) ruling out an effect of ATA on the affinity of the immunoprecipitating antibody for 
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PMCA4. This result indicates that ATA promotes the association between PMCA4 and eNOS. 
Accordingly, functional experiments in HUVECs showed that ATA (250 nM) significantly 
attenuate NO synthesis in VEGF-stimulated cells (Fig 5B), excluding NO as an effector of the 
enhancement in angiogenesis mediated by ATA.        
3.4. Low ATA levels are not toxic to endothelial cells  
Our observations suggest that inhibition of PMCA4 with ATA has therapeutic potential for the 
promotion of blood vessel formation in situations characterized by insufficient angiogenesis. 
To evaluate this possibility we first monitored for any effect of ATA on endothelial cell viability. 
Exposure of HUVECs to 250 nM ATA did not affect proliferation or cell viability (Fig 6A), and 
also had no effect on the VEGF-induced phosphorylation (activation) status of Erk1/2 (Fig 6B), 
indicating that low ATA concentrations do not modify the activity of this proliferative signal 
transduction pathway.  
In contrast, long-term exposure of HUVECs to a higher concentration (20 µM) reduced cell 
viability (Fig S3A) and abolished the ability of VEGF-stimulated HUVECs to form capillary-like 
structures in matrigel assays (Fig S3B). To investigate the reasons underlying the toxic effects 
of high concentrations of ATA on endothelial cells, we first determined whether micromolar 
concentrations of ATA might induce any changes in the pH of the culture medium. Analysis of 
cultures of HUVECs incubated in medium containing vehicle (DMSO), or ATA at low (0.25 μM) 
or high (20 μM) concentration for different periods showed no differences in the pH of the 
medium (Fig S3C). Another possibility to explain the harmful effect of 20 μM ATA on the 
viability of endothelial cells could be that high ATA concentrations in the culture medium might 
result in deleterious osmotic stress on the cells. To test this possibility we checked the 
activation of ATF-2, a transcription factor well-known to respond to osmotic stress [30, 31], in 
HUVECs grown in tissue culture medium containing low or high concentrations of ATA. No 
changes in the phosphorylation (activation) status of ATF-2 were detected in cells grown in 
medium containing 20 μM ATA compared to cells grown in 0.25 μM ATA or vehicle (DMSO) 
(Fig S3D). Osmotic stress induced by high concentration of NaCl in the medium resulted in 
ATF-2 phosphorylation confirming the suitably of the assay (Fig S3D).  
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To analyse potential toxic effects of ATA in a more physiological setting, we treated zebrafish 
embryos with increasing ATA concentrations. Consistent with the in vitro data, low ATA 
concentrations (50-100 µM) caused no significant damage to embryos, which developed a 
normal vascular anatomy (Fig S4). In contrast, exposure to ATA concentrations above 100 µM 
was associated with embryo death (Fig S4).  
Although our results demonstrate proof-of-concept for pharmacological targeting of PMCA4 in 
therapeutic approaches, refined versions of ATA with high specificity for PMCA4 will be 
required to design efficient and safe clinical interventions. 
3.5. ATA enhances post-ischaemic hindlimb perfusion in vivo 
To evaluate in vivo the therapeutic potential of PMCA4 inhibition to promote reperfusion of 
ischaemic tissues, we used the mouse hindlimb ischaemia model. We have used two surgical 
approaches to induce different levels of ischaemia in the lower limb of mice [32, 33]. In a first 
approach, limb ischaemia was induced by proximal and distal ligation of a short fragment of 
the femoral artery with excision of the intervening segment. This procedure induces limb 
ischaemia by significantly reducing the flow of blood to the limb but still maintains a low degree 
of blood flow to the muscle. Initially we chose this model to maintain a low degree of blood flow 
that could mediate the delivery of ATA to the ischaemic organ. To evaluate the effect of ATA 
on this setting, vehicle (DMSO) or ATA was administered intraperitoneally 2 hours after 
surgery and daily for 3 more days. Given the harmful effects of high ATA concentrations (Fig 
S3 and S4) we selected a dose of 5 mg/Kg/day, which is not associated with damage in mice 
[34]. Laser Doppler imaging analysis of blood flow performed 4 days after surgery revealed a 
significant increase in the reperfusion of post-ischaemic limbs treated with ATA (Fig 7). To 
explore whether ATA would be able to exert the same effect in a model of deep acute 
ischaemia, in a separate set of experiments we performed femoral ligation and excision of the 
intervening segment but on this occasion we ligated and excised a longer femoral segment. 
This procedure totally blunted blood flow to the lower limb (Fig S5A). As expected, loss of 
blood flow resulted in a strong upregulation of VEGF expression in the ischaemic limb (Fig 
S6). Blood flow to the ischaemic limb was progressively recovered along time (Fig S5A). In 
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concurrence with our initial data, administration of ATA to these animals also enhanced 
significant reperfusion of the ischaemic limb (Fig S5A-B) although, in this case, administration 
of ATA for 7-10 days was required to detect the enhancement of blood flow mediated by the 
drug. It is likely that in this model, a longer period of ATA administration is required because 
ATA delivery to the ischaemic area is compromised during the first days post-surgery due to 
the absence of blood flow.      
These data obtained using in vivo animal models reinforce the therapeutic potential of 
pharmacological targeting of PMCA4 to promote tissue reperfusion in patients with ischaemic 
cardiovascular disease.  
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4. Discussion 
In this study, we demonstrate that inhibition of the plasma membrane calcium ATPase 4 
(PMCA4) with low concentrations of the small polyaromatic compound aurintricarboxylic acid 
(ATA) significantly enhances VEGF-induced angiogenic processes. Our results show proof-of-
concept for targeting PMCA4 therapeutically to improve VEGF-based pro-angiogenic 
interventions in patients with ischaemic cardiovascular disease. In this work we have used 
ATA to inhibit the function of PMCA4. The feasibility of ATA as a clinical treatment has yet to 
be tested, but pre-clinical studies in animal models have revealed potential clinical applications 
in the treatment of cardiac hypertrophy [34], experimental autoimmune encephalomyelitis [35], 
sepsis [36], and myocardial ischaemia-reperfusion injury [37].  
Our results show that high levels of ATA strongly reduce endothelial cell viability and abolish 
tube formation. Consistent with our results, Lipo et al. [38] reported that increasing ATA 
concentrations diminish the ability of endothelial cells to form tubular-like structures in matrigel 
assays. Furthermore, in the same study, the authors report that intravitreal injection of 1.5 µg 
ATA in 2µl 10% DMSO (corresponding to 1.78 mM ATA) into mice strongly attenuates laser-
induced choroidal neovascularization. It is highly likely that the reduced ocular vascularization 
observed by Lipo et al. [38] results from the toxicity associated with high ATA concentrations, 
an interpretation supported by our experiments in zebrafish embryos (Fig S4) and those 
reported by Smee et al. [39] in mice. Furthermore, 5-20 µM ATA has been shown to reduce 
the growth rate of fibroblasts [40] and smooth muscle cells [41]. In this work we have not 
identified the mechanisms underlying the harmful effect on endothelial cell viability exerted by 
high levels of ATA but, at these concentrations, ATA has been reported to non-specifically 
inhibit the action of nucleases [42], calpain [43] and several chemokine receptors [35], 
suggesting possible explanations for the toxicity of high-concentration ATA. The deleterious 
effects exerted by ATA at high concentrations indicate that refined, highly selective versions of 
this molecule will be required for efficient therapeutic interventions to treat patients with 
chronic ischaemic disease without associated harmful side-effects.  
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Mechanistically, ATA enhances VEGF-induced activation of the calcineurin/NFAT pathway in 
endothelial cells, in turn boosting calcineurin-dependent angiogenic processes such as 
endothelial cell migration and tubular morphogenesis. Our data indicate that ATA increases 
calcineurin signalling by disrupting its interaction with calcineurin at the plasma membrane. At 
present, we do not know the molecular process by which ATA disrupts the PMCA4/calcineurin 
complex. A possible explanation is masking by ATA of the calcineurin-interacting region in 
PMCA4 (amino acids 428 to 651 in human PMCA4b) [21]. Supporting this possibility, ATA 
inhibits hepatitis C helicase by a similar mechanism, binding to a defined region in the enzyme 
and thereby blocking interaction with nucleic acids [44]. However, a different picture emerges 
from analysis of the effect of ATA on PMCA4 binding to endothelial nitric oxide synthase 
(eNOS), which interacts with the same PMCA4 domain as calcineurin [26]. Rather than 
decreasing the interaction, ATA promotes association between PMCA4 and eNOS (Fig 5A). 
The opposite effects of ATA on PMCA4 binding to calcineurin or eNOS suggests that ATA is 
unlikely to be an allosteric competitor with partner proteins for binding to the 428-651 PMCA4 
domain. It will be interesting in future research to fully define the molecular events implicated 
in ATA-mediated disruption of PMCA4/calcineurin interaction and the differential effect of ATA 
on PMCA4 binding to calcineurin or eNOS. 
The results presented here establish a key role for the calcineurin/NFAT signalling pathway in 
the enhancement of VEGF-induced angiogenesis upon inhibition of PMCA4 with low ATA 
concentrations. We have previously reported that PMCA4 also downregulates eNOS activity 
and NO production in endothelial cells (26). Here, we show that ATA attenuates VEGF-
induced nitric oxide production in endothelial cells, suggesting that NO signalling is not 
implicated in the enhancement of angiogenesis mediated by ATA; however, our results do not 
exclude the potential participation of other signalling pathways. Further investigations into the 
molecular mechanisms underlying ATA-mediated enhancement of VEGF signalling promise to 
reveal novel molecular targets for improving pro-angiogenic therapy. 
Our in vivo experiments in animal models of experimentally induced hindlimb ischaemia show 
that ATA enhances reperfusion of post-ischaemic limbs. Given that our experiments using 
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HUVECs in culture have shown that ATA markedly enhances VEGF-induced angiogenesis in 
vitro, it is likely that the increase in reperfusion of post-ischaemic limbs induced by ATA 
involves increased revascularisation of the muscle, although a full characterisation of the effect 
of ATA on angiogenesis in vivo will require further investigations.    
The present study indicates that targeting PMCA4 could improve VEGF-based pro-angiogenic 
interventions, highlighting the clinical potential of using PMCA4 inhibitors for the treatment of 
ischaemic cardiovascular disease. Interestingly, in addition to the ATA-mediated increase in 
reperfusion of ischaemic limbs, a trend to increase blood flow in non-ischaemic (sham-
operated) muscle was also observed in the animals treated with ATA (Fig 7 and S5) although 
these differences did not reach statistical significance (P=0.0558). Our findings in cultured 
HUVECs have shown that ATA enhances blood vessel formation in the presence of VEGF but 
does not have any effect when it is added to serum-starved cells (Fig 4). We speculate that the 
increased blood flow in non-ischaemic limbs of animals treated with ATA might be the result of 
ATA acting in conjunction with low physiological levels of VEGF normally present in the 
muscle (Fig S6). We think this is extremely interesting from a therapeutic point of view, as one 
of the main obstacles for success of current VEGF-based therapeutic strategies is the difficulty 
to achieve high ectopic expression of VEGF in the ischaemic organ [5]. In fact, although it is 
thought that VEGF-based gene therapy is the best way forward in future therapeutic 
approaches, adenoviral vectors only transduce a small percentage of the target cells in 
humans [45]. Thus, selective PMCA4 inhibitors might be useful co-adjuvants in VEGF-based 
gene therapy strategies to enhance reperfusion of ischaemic tissues even in situations where 
expression of ectopic VEGF is not very high. Our in vivo data in this work do not allow 
evaluating the efficiency of single versus combined ATA/VEGF therapies. Further studies are 
required to analyse the pharmacokinetics of single and combined ATA/VEGF therapies in 
preclinical animal models of cardiovascular ischaemic disease.    
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Figure Legends 
Figure 1. ATA enhances VEGF-induced activation of calcineurin/NFAT signalling in 
endothelial cells. (A) HUVECs infected with the NFAT-dependent luciferase reporter 
adenovirus AdNFAT-Luc (MOI=50) were treated with VEGF (25 ng/ml) or left untreated 
(control) in the presence of ATA (250 nM) or vehicle (DMSO). Cells were lysed 6 hours post 
stimulation and luciferase activity was determined as an index of calcineurin/NFAT pathway 
activity. Results are expressed as fold-induction over the calcineurin/NFAT activity in DMSO-
treated control cells. Data are shown as mean ± SE, n=12, obtained from 3 independent 
experiments. ns=non-significant; ***, P≤0.005; ####, P≤0.001; &&&&, P≤0.001 (one-way ANOVA 
with post hoc Tukey´s comparison test). (B) HUVECs treated as in (A) were lysed 4 hours post 
stimulation, and protein lysates were analysed by western blot to determine the levels of 
RCAN1.4 and tubulin. RCAN1.4 levels were normalised to the amount of tubulin in each 
sample. Data are shown as mean ± SE, n=6, obtained from 3 independent experiments.*, 
P≤0.05 (unpaired two-tailed Student’s t test) for comparison of cells treated with ATA vs 
vehicle (DMSO). 
Figure 2. ATA releases calcineurin from interaction with PMCA4 in the endothelial cell 
plasma membrane. (A) Western blot analysis of calcineurin A (CnA), PMCA4, and cadherin in 
the plasma membrane protein fraction of serum-starved HUVECs treated for 4 hours with 
VEGF (25 ng/ml) plus ATA (250 nM) or vehicle (DMSO). The histogram shows the levels of 
membrane-associated calcineurin normalised to the amount of cadherin present in each 
sample. (B) Western blot analysis of calcineurin A (CnA), PMCA4 and tubulin (Tub) in total 
lysates prepared with Laemmli buffer from HUVECs treated as in (A). The histogram shows 
levels of total calcineurin normalised to the amount of tubulin present in each sample. (C) 
Immunoprecipitation/western blot analysis of calcineurin (CnA) and PMCA4 in protein 
complexes immunoprecipitated with anti-calcineurin antibody from total protein lysates of 
HUVECs treated as in (A). The histogram shows levels of co-precipitated PMCA4 normalised 
to the amount of calcineurin precipitated in each assay. (A-C) Blots are representative of 3 
independent experiments. Histograms show data as mean ± SE, obtained from 3 independent 
experiments. **, P≤0.01 (unpaired two-tailed Student’s t test) for comparison of the plasma 
membrane levels of calcineurin in VEGF-stimulated cells treated with ATA vs vehicle (DMSO). 
*, P≤0.05 (unpaired two-tailed Student’s t test) for comparison of co-precipitated PMCA4 in 
VEGF-stimulated HUVECs treated with ATA vs vehicle (DMSO). ns=non-significant. 
Figure 3 ATA increases endothelial cell motility by inhibiting PMCA4 and disrupting the 
PMCA4/calcineurin interaction. Representative images of wound-healing migration assays 
performed with HUVECs (A), PMCA4+/+ or PMCA4-/- MLECs (B), and AdLacZ- or AdID4-
infected HUVECs (C) incubated in culture medium supplemented with VEGF (25 ng/ml) in the 
presence of ATA (250 nM) or vehicle (DMSO). (A) Data are shown as mean ± SE, n=9, 
obtained from 3 independent experiments. ***, P≤0.005 (unpaired two-tailed, Student’s t test) 
for comparison of cells treated with ATA vs vehicle (DMSO). (B) Data are shown as mean ± 
SE, n=6, obtained from 3 independent experiments. Differences were analysed for statistical 
significance by one-way ANOVA with post hoc Tukey´s comparison test. ***, P≤0.005 for 
comparison of migration by PMCA4+/+ MLECs treated with ATA vs vehicle (DMSO). ####, 
P≤0.001 for comparison of motility in wild-type (+/+) vs PMCA4 knockout (-/-) MLECs. ns=non-
significant. (C) Data are shown as mean ± SE, n=3, obtained from 3 independent experiments. 
Differences were analysed for statistical significance by one-way ANOVA with post hoc 
Tukey´s comparison test. *, P≤0.05 for comparison of motility in AdLacZ-infected cells treated 
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with ATA vs vehicle (DMSO). ###, P≤0.005 for comparison of migration in cells infected with 
AdLacZ vs AdID4. ns=non-significant. Images in (A-C) were taken at time zero and after 
incubation for 24 hours. The migrated area was calculated by subtracting the value of the non-
migrated area from the wound area at time zero, and expressing this as a percentage of the 
total area at time zero. Scale bars, 1000 µm. 
Figure 4 ATA enhances endothelial cell tubular morphogenesis induced by VEGF but 
not by bFGF. HUVECs plated on Growth-Factor Reduced Matrix (Geltrex) in Medium 200 
containing 2% FBS, were treated when indicated with VEGF (50 ng/ml) (A) or bFGF (50 ng/ml) 
(C) in the presence of ATA (250 nM) or vehicle (DMSO). Images show representative fields 
from experiments quantified in the histogram. Data are shown as mean ± SE, n=6 in (A) and 
n=4 in (C), and were obtained from 3 and 2 independent experiments, respectively. (A) 
ns=non-significant; ***, P≤0.005; #, P≤0.05; ####, P≤0.001; &, P≤0.05; &&&&, P≤0.001 (unpaired 
two-tailed Student’s t test). (C) ns=non-significant; **, P≤0.01; ***, P≤0.005; ### , P≤0.005 (one-
way ANOVA with post hoc Tukey’s comparison test). (B) Tubular morphogenesis analysis in 
HUVECs transfected with a PMCA4-specific siRNA (si-PMCA4) or a non-targeting control 
siRNA (si-NT). Transfected cells were plated on Growth-Factor Reduced Matrix (Geltrex) in 
Medium 200 containing 2% FBS, and treated with VEGF (50 ng/ml) in the presence of ATA 
(250 nM) or vehicle (DMSO). Images show representative fields from experiments quantified in 
the histogram. Data are shown as mean ± SE, n=9 obtained from 3 independent experiments. 
ns=non-significant; ***, P≤0.005 (one-way ANOVA with post hoc Tukey’s comparison test). (A-
C) Scale bars, 1000 µm.  
Figure 5 ATA treatment potentiates the PMCA4/eNOS interaction and attenuates nitric 
oxide synthesis in endothelial cells stimulated with VEGF. (A) Serum-starved HUVECs 
were treated with VEGF (25 ng/ml) and ATA (250 nM) or vehicle (DMSO) for 5 minutes. 
Protein lysates were immunoprecipitated with the anti-PMCA 5F10 monoclonal antibody, and 
levels of PMCA4 and eNOS in the immunoprecipitated proteins analysed by western blot. 
Histogram shows levels of co-precipitated eNOS normalised to the amount of PMCA4 
precipitated in each assay. Data are shown as mean ± SE obtained from 3 independent 
experiments. ** indicates statistically significant differences (P≤0.01, according to unpaired, 
two-tailed Student’s t test) in the levels of eNOS co-precipitated in samples treated with ATA 
vs DMSO. Western blot images are representative of 3 independent immunoprecipitation 
experiments. (B) HUVECs were treated as indicated in (A). Intracellular levels of nitric oxide 
were determined by staining cells with the NO-sensitive dye DAF-FM. Images showing 
microscopy fields of DAF-FM staining in cells are representative of 2 independent 
experiments. Scale bars, 20 µm. 
Figure 6 Low concentration ATA is not toxic to endothelial cells. (A) MTT assay cell 
viability in HUVECs after overnight incubation (t=0) and incubation for 3 and 6 days in medium 
supplemented with VEGF (25 ng/ml) in the presence of ATA (250 nM) or vehicle (DMSO). 
Data are shown as mean ± SE, n=3, obtained from 3 independent experiments. (B) Western 
blot analysis of the phosphorylation (activation) status of Erk1-2 proteins in HUVECs 
stimulated as indicated with VEGF for 5 minutes in the presence of ATA (250 nM) or vehicle 
(DMSO). Data are shown as mean ± SE, n=5, obtained from 3 independent experiments. 
Erk1-2 phosphorylation levels were normalized to the amount of total Erk1-2 present in each 
sample. Data are expressed as the fold-induction in Erk1-2 phosphorylation relative to the 
value in unstimulated cells. ns=non-significant. 
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Figure 7 Administration of ATA at low concentration boosts post-ischaemic hind limb 
perfusion in mice. Representative laser Doppler images showing blood flow at 4 days after 
surgery in sham-operated non-ischaemic legs (S) and femoral-ligated ischaemic legs (I) of 
mice receiving ATA (5 mg/kg/day) or vehicle (DMSO) by intraperitoneal injection. Data are 
shown as mean ± SE, n=7, obtained from 2 independent experiments. **, P≤0.01 (unpaired 
two-tailed Student’s t test) for comparison of ischaemic-leg blood flow in mice receiving ATA 
vs vehicle. ns=non-significant.  
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Western blot antibodies 
Western blot membranes were incubated in TBS-T (TBS, 0.05% Tween 20), overnight, at 
4°C with a solution containing one of the following antibodies; for detection of RCAN1.4 with 
a 1:1000 dilution of a rabbit anti-DSCR1 polyclonal antibody (Sigma), for PMCA4 detection 
with a 1:500 dilution of the anti-PMCA4-specific monoclonal antibody JA3 (Santa Cruz 
Biotechnology), for detection of calcineurin with a 1:1000 dilution of a anti-calcineurin A 
monoclonal antibody (BD Biosciences), for detection of eNOS with a 1:5000 solution of a 
rabbit polyclonal anti-eNOS (Sigma), for detection of tubulin with a 1:2500 dilution of a 
mouse monoclonal anti-tubulin antibody (Sigma), for detection of total Erk with a 1:1000 
dilution of a rabbit anti-Erk1/2 antibody (Cell Signalling), for detection of phosphorylated 
(activated) Erk1/2 with a 1:000 dilution of anti-phospho-Erk1/2 (Thr202/Tyr204) antibody 
(Cell Signalling), for detection of total ATF-2 with a 1:1000 dilution of a rabbit anti-ATF-2 
antibody (Cell Signalling), for detection of phosphorylated (activated) ATF-2 with a 1:1000 
dilution of anti-phospho-ATF-2 (Thr71) antibody (Cell Signalling). 
After incubation with primary antibodies, membranes were washed with TBS-T, and then 
incubated in either a 1:5000 dilution of peroxidase-conjugated sheep anti-mouse 
immunoglobuilin antibody (Sigma) or 1:5000 dilution of peroxidase-conjugated donkey anti-
rabbit immunoglobulin antibody (GE Healthcare) depending of the origin of the primary 
antibody. Bound antibodies were detected by ECL.  






